160 related articles for article (PubMed ID: 36089725)
41. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
42. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
43. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
44. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
[TBL] [Abstract][Full Text] [Related]
45. Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer.
Rajput K; Edwards L; Brock P; Abiodun A; Simpkin P; Al-Malky G
Int J Pediatr Otorhinolaryngol; 2020 Nov; 138():110401. PubMed ID: 33152988
[TBL] [Abstract][Full Text] [Related]
46. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
47. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
48. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
49. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
50. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Kushner BH; Budnick A; Kramer K; Modak S; Cheung NK
Cancer; 2006 Jul; 107(2):417-22. PubMed ID: 16779793
[TBL] [Abstract][Full Text] [Related]
51. Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.
Mukherjea D; Dhukhwa A; Sapra A; Bhandari P; Woolford K; Franke J; Ramkumar V; Rybak L
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):965-982. PubMed ID: 32757852
[TBL] [Abstract][Full Text] [Related]
52. Clinically accurate assessment and grading of ototoxicity.
Chang KW
Laryngoscope; 2011 Dec; 121(12):2649-57. PubMed ID: 22109766
[TBL] [Abstract][Full Text] [Related]
53. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats.
Paksoy M; Ayduran E; Sanlı A; Eken M; Aydın S; Oktay ZA
Med Oncol; 2011 Jun; 28(2):615-21. PubMed ID: 20300971
[TBL] [Abstract][Full Text] [Related]
54. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
55. The Sustained-Exposure Dexamethasone Formulation OTO-104 Offers Effective Protection against Cisplatin-Induced Hearing Loss.
Fernandez R; Harrop-Jones A; Wang X; Dellamary L; LeBel C; Piu F
Audiol Neurootol; 2016; 21(1):22-9. PubMed ID: 26789647
[TBL] [Abstract][Full Text] [Related]
56. Assessment of cisplatin-induced ototoxicity using derived-band ABRs.
Coupland SG; Ponton CW; Eggermont JJ; Bowen TJ; Grant RM
Int J Pediatr Otorhinolaryngol; 1991 Oct; 22(3):237-48. PubMed ID: 1752735
[TBL] [Abstract][Full Text] [Related]
57. [Ototoxicity of cisplatin].
Ivanov SA; Zhuravskiĭ SG; Galagudza MM
Vestn Otorinolaringol; 2012; (4):82-7. PubMed ID: 23035268
[TBL] [Abstract][Full Text] [Related]
58. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
59. Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma.
Rubin JS; Wadler S; Beitler JJ; Haynes H; Rozenblit A; McGill F; Goldberg G; Runowicz C
J Laryngol Otol; 1995 Aug; 109(8):744-7. PubMed ID: 7561498
[TBL] [Abstract][Full Text] [Related]
60. Ototoxicity monitoring in children treated with platinum chemotherapy.
Brooks B; Knight K
Int J Audiol; 2018 Sep; 57(sup4):S34-S40. PubMed ID: 28737048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
